Accuray Incorporated (ARAY)

Price$0.34

Value ScoreA

Growth ScoreD

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-76.25%

Price vs S&P 500 (4W)22.55%

VGM Score41.30

Market Capitalization$40.67M

All Metrics

P/CF (Annual)14.22x

Book Value / Share (Quarterly)$0.35

P/TBV (Annual)2.15x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)2.17%

Cash Flow / Share (Quarterly)$-0.22

Price vs S&P 500 (YTD)-66.45%

Gross Margin (TTM)26.90%

Net Profit Margin (TTM)-10.76%

EPS (TTM)$-0.38

10-Day Avg Trading Volume5.97M

EPS Excl Extra (TTM)$-0.38

Revenue Growth (5Y)3.67%

EPS (Annual)$-0.02

ROI (Annual)-0.73%

Gross Margin (Annual)32.05%

Net Profit Margin (5Y Avg)-1.75%

Cash / Share (Quarterly)$0.32

Revenue Growth QoQ (YoY)-7.42%

ROA (Last FY)-0.34%

Revenue Growth TTM (YoY)-7.88%

EBITD / Share (TTM)$-0.16

ROE (5Y Avg)-14.58%

Operating Margin (TTM)-6.13%

Cash Flow / Share (Annual)$-0.01

P/B Ratio0.98x

P/B Ratio (Quarterly)1.11x

Net Income / Employee (Annual)$-1,600

EV / Revenue (TTM)0.34x

Net Interest Coverage (TTM)1.15x

ROA (TTM)-10.12%

EV / EBITDA (TTM)22.69x

EPS Incl Extra (Annual)$-0.02

Current Ratio (Annual)1.65x

Quick Ratio (Quarterly)0.61x

3-Month Avg Trading Volume2.61M

52-Week Price Return-77.01%

Revenue / Employee (TTM)$432,900

Tangible BV / Share (Quarterly)$0.21

P/S Ratio (Annual)0.09x

Asset Turnover (Annual)0.97x

52-Week High$2.10

Operating Margin (5Y Avg)1.53%

EPS Excl Extra (Annual)$-0.02

CapEx CAGR (5Y)2.75%

Tangible BV CAGR (5Y)0.83%

26-Week Price Return-64.86%

Quick Ratio (Annual)0.85x

13-Week Price Return-29.71%

Total Debt / Equity (Annual)1.68x

Current Ratio (Quarterly)1.42x

Enterprise Value$147.79M

Revenue / Share Growth (5Y)1.09%

Asset Turnover (TTM)0.94x

Book Value / Share Growth (5Y)0.66%

Revenue / Employee (Annual)$463,100

Inventory Turnover (Annual)2.23x

Pretax Margin (Annual)0.25%

Cash / Share (Annual)$0.51

3-Month Return Std Dev154.01%

Gross Margin (5Y Avg)35.20%

Net Income / Employee (TTM)$-46,600

EBITDA CAGR (5Y)-5.05%

ROE (Last FY)-1.96%

Net Interest Coverage (Annual)-1.55x

EPS Basic Excl Extra (Annual)$-0.02

P/FCF (TTM)1.44x

Receivables Turnover (TTM)5.85x

EV / Free Cash Flow (TTM)9.50x

Total Debt / Equity (Quarterly)3.48x

EPS Incl Extra (TTM)$-0.38

Receivables Turnover (Annual)5.18x

ROI (TTM)-23.18%

P/S Ratio (TTM)0.09x

Pretax Margin (5Y Avg)-1.11%

Revenue / Share (Annual)$4.46

Tangible BV / Share (Annual)$0.58

Price vs S&P 500 (52W)-104.06%

Year-to-Date Return-55.43%

5-Day Price Return-3.41%

EPS Normalized (Annual)$-0.02

ROA (5Y Avg)-1.61%

Net Profit Margin (Annual)-0.35%

Month-to-Date Return-3.41%

Cash Flow / Share (TTM)$-0.02

EBITD / Share (Annual)$0.15

Operating Margin (Annual)2.03%

LT Debt / Equity (Annual)1.52x

P/CF (TTM)8.95x

ROI (5Y Avg)-3.36%

LT Debt / Equity (Quarterly)3.21x

EPS Basic Excl Extra (TTM)$-0.38

P/TBV (Quarterly)1.87x

P/B Ratio (Annual)1.74x

Inventory Turnover (TTM)2.07x

Pretax Margin (TTM)-10.19%

Book Value / Share (Annual)$0.72

Price vs S&P 500 (13W)-40.21%

Beta1.35x

P/FCF (Annual)14.22x

Revenue / Share (TTM)$3.45

ROE (TTM)-77.48%

52-Week Low$0.25

vGradeA

gGradeD

mGradeF

vgmGradeC

Show chart for

Earnings Surprise History

Q3 26-0.09est. -0.05

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.38

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
ARAYAccuray Incorporated	A	D	F	$0.34
SYKStryker Corporation	C	C	C	$305.66
MMM3M Company	C	F	C	$153.76
BSXBoston Scientific Corp.	C	B	D	$48.55
MDLNMedline Inc. Class A common stock	C	D	D	$33.61
BDXBecton, Dickinson and Co.	B	C	C	$151.16
RMDResMed Inc.	C	B	C	$196.04
DXCMDexCom, Inc.	C	B	C	$72.86
WSTWest Pharmaceutical Services, Inc.	D	C	B	$314.50
SOLVSolventum Corporation	C	D	B	$81.01
PENPenumbra, Inc.	F	C	B	$320.53

About

Accuray manufactures the CyberKnife, a precision radiation oncology system for treating cancers and tumors throughout the body. The system automatically detects and corrects for tumor and patient movement in real-time, delivering high-dose radiation with sub-millimeter accuracy while patients breathe normally and without requiring manual intervention. This technology sets the standard for precision radiation therapy in cancer treatment.